


Microneedle Array for Universal Vaccine Delivery Developed

APRIL 22ND, 2020
 MEDGADGET EDITORS
 MEDICINE, PUBLIC HEALTH



Microneedle arrays (MNAs) are a promising way of delivering vaccines into the body. They are nearly pain-free and can penetrate a substantial portion of the skin, which is considered an excellent place to inject vaccines because of the skin's sensitive and very reactive immune network. Injecting small amounts of a vaccine strategically into the skin can, therefore, produce a significantly more intense immune response than that created using conventional hypodermic needles.

A team at the University of Pittsburgh School of Medicine have now developed a microneedle array patch that can carry live or attenuated viral vectors, as well as adjuvant compounds to boost vaccine effectiveness. The patch is very impressive at activating a strong immune response.

The patch has 400 nearly microscopic needles that are made from sugar mixed with the viral vectors and adjuvant that are required for the application. When pressed against the skin, reportedly the patch feels just like touching a piece of Velcro. The needles punch through the upper layer of the skin where they absorb fluids from the skin that cause them to dissolve and the vaccine compounds within to begin their activity within the body. The researchers believe that this approach should improve the cellular immune response to vaccinations.

“We are developing this new delivery technology because while traditional vaccines are often effective in inducing antibody responses, they frequently fail to generate the cellular responses that are essential to prevent or treat many cancers or infectious diseases,” said Louis D. Faló, Jr., MD, PhD, lead author of the study appearing in *Journal of Investigative Dermatology*, in an Elsevier press release.

The researchers demonstrated their approach by utilizing a live adenovirus-encoded antigen combined with polyinosinic:polycytidylic acid (poly I:C), an immunostimulant, to generate a large production of antibodies and a strong cellular immune response in laboratory mice.

“Remarkably,” added Dr. Faló, “the MNA vaccine platforms incorporating both antigen-encoding adenovirus and poly I:C augmented the destruction of targeted cells significantly compared to MNA-delivery of the same adenovirus alone.”

The researchers claim that in addition to a better immune response, their patches are cheap to manufacture, easy to integrate with other vectors, and can be stored for extended periods of time.

The researchers also found that the MNAs integrating both poly I:C and adenovirus retained their immunogenicity after one month of storage at 4° C. MNA-delivered vaccines also have advantages in their ease of fabrication, application, and storage compared with other vaccine delivery platforms.

“Our results suggest that multicomponent MNA vaccine platforms uniquely enable delivery of both adjuvant and antigen-encoding viral vectors to the same skin microenvironment, resulting in improved immunogenicity including cellular immune responses,” added Dr. Faló. “This MNA delivery approach could improve the effectiveness of adenoviral vaccines now in development for the prevention of coronavirus disease (COVID-19).”

Study in *Journal of Investigative Dermatology*: [Improved cutaneous genetic immunization by microneedle array delivery of an adjuvanted adenovirus vaccine.](#)

Via: [Elsevier](#)

We recommend

New, More Effective Flu Vaccine Delivered Using Dissolvable Microneedle Patch |
 Editors, Medgadget, 2017

Delivering Vaccine With Dissolving Microneedles
 Wouter Stomp, Medgadget, 2010

Stainless Steel Microneedles for Flu Vaccine Delivery
 Editors, Medgadget, 2009

4D Printing to Make Barbs for Microneedle Array
 Medgadget Editors, Medgadget, 2020

Microneedle Array Allows Real-Time Monitoring Of Body Chemistry |
 Medgadget

TransDerm Awarded \$4M Grant to Develop RNAi Treatment for Skin Disease
 GenomeWeb, 2011

A Patch to Deliver Vaccine
 GenomeWeb, 2013

Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic
 L.H. Sehn et al., Current Oncology, 2020

Seventh Sense Biosystems, Miraca Sign Distribution, Investment Deal
 staff reporter, 360Dx, 2019

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
 McInnes et al., Lancet, 2020

Powered by **TREND MD**



Medgadget Editors

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.



SPONSORED

Breaking Records - Traditional FDA 510(k) Cleared in 18 Days

Naviswiss Reaches 1000th Navigated THR

TEQ expands total solution approach to serve high-quality packaging to growing

ManlyWellness Releases its 2020 State of Mental Health in America Survey Results

Sensoria Wellness Coach in IoT Smart Cushion for Wheelchair Users

INTERVIEWS & REVIEWS

Hyperpolarized Gas MRI for Pulmonary Disease Assessment: Interview with

Keep A Breast Foundation and Carbon Health Partner on Self-Check App

Jada System for Postpartum Hemorrhage: Interview with Rob Binney, CEO of Alydia

Pivoting to PPE - A Plastic Manufacturer's Response to the Covid Pandemic: Interview

UV Disinfection of Medical Equipment: Interview with Jeremy Starkweather,

Targeted Therapeutics for Critical Illnesses: Interview with Jason Springs, CEO of

Real-Time Urine Flow Rate Measurement: Interview with Christopher Strafaci, VP of

